These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18158862)

  • 1. Molecular markers and targets for colorectal cancer prevention.
    Janakiram NB; Rao CV
    Acta Pharmacol Sin; 2008 Jan; 29(1):1-20. PubMed ID: 18158862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials.
    Scott EN; Gescher AJ; Steward WP; Brown K
    Cancer Prev Res (Phila); 2009 Jun; 2(6):525-30. PubMed ID: 19470784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs are novel biomarkers of colorectal cancer.
    Aslam MI; Taylor K; Pringle JH; Jameson JS
    Br J Surg; 2009 Jul; 96(7):702-10. PubMed ID: 19526617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic biomarkers for molecular cancer therapeutics.
    Sarker D; Workman P
    Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biomarker for chemotherapy in patients with colorectal cancer].
    Matsusaka S
    Gan To Kagaku Ryoho; 2009 Jan; 36(1):11-4. PubMed ID: 19151559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy for colorectal cancer: mapping the way.
    Mocellin S; Lise M; Nitti D
    Trends Mol Med; 2005 Jul; 11(7):327-35. PubMed ID: 15950539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective.
    Grothey A
    Stat Methods Med Res; 2008 Oct; 17(5):529-35. PubMed ID: 18285442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.
    Kelloff GJ; Lippman SM; Dannenberg AJ; Sigman CC; Pearce HL; Reid BJ; Szabo E; Jordan VC; Spitz MR; Mills GB; Papadimitrakopoulou VA; Lotan R; Aggarwal BB; Bresalier RS; Kim J; Arun B; Lu KH; Thomas ME; Rhodes HE; Brewer MA; Follen M; Shin DM; Parnes HL; Siegfried JM; Evans AA; Blot WJ; Chow WH; Blount PL; Maley CC; Wang KK; Lam S; Lee JJ; Dubinett SM; Engstrom PF; Meyskens FL; O'Shaughnessy J; Hawk ET; Levin B; Nelson WG; Hong WK;
    Clin Cancer Res; 2006 Jun; 12(12):3661-97. PubMed ID: 16778094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing preclinical mouse models to inform human clinical cancer trials.
    Gutmann DH; Hunter-Schaedle K; Shannon KM
    J Clin Invest; 2006 Apr; 116(4):847-52. PubMed ID: 16585951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs in clinical oncology: at the crossroads between promises and problems.
    Metias SM; Lianidou E; Yousef GM
    J Clin Pathol; 2009 Sep; 62(9):771-6. PubMed ID: 19734473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
    Jiang W; Freidlin B; Simon R
    J Natl Cancer Inst; 2007 Jul; 99(13):1036-43. PubMed ID: 17596577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
    Armstrong AJ; Febbo PG
    Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point.
    Arber N
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):1852-7. PubMed ID: 18708371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New mechanisms and therapeutic potential of curcumin for colorectal cancer.
    Villegas I; Sánchez-Fidalgo S; Alarcón de la Lastra C
    Mol Nutr Food Res; 2008 Sep; 52(9):1040-61. PubMed ID: 18655004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in oncology: trials and tribulations.
    Taube SE
    Ann N Y Acad Sci; 2009 Oct; 1180():111-8. PubMed ID: 19906265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flavonoids and intestinal cancers.
    Pierini R; Gee JM; Belshaw NJ; Johnson IT
    Br J Nutr; 2008 May; 99 E Suppl 1():ES53-9. PubMed ID: 18503735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist.
    Søreide K; Nedrebø BS; Knapp JC; Glomsaker TB; Søreide JA; Kørner H
    Surg Oncol; 2009 Mar; 18(1):31-50. PubMed ID: 18672360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The convergent development of molecular-targeted drugs for cancer treatment and prevention.
    Lippman SM; Heymach JV
    Clin Cancer Res; 2007 Jul; 13(14):4035-41. PubMed ID: 17634526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoscopy, morphology, morphometry and molecular markers: predicting cancer risk in colorectal adenoma.
    Søreide K; Nedrebø BS; Reite A; Thorsen K; Kørner H
    Expert Rev Mol Diagn; 2009 Mar; 9(2):125-37. PubMed ID: 19298137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.